Previous
Previous

FORE Biotherapeutics announces $75M in Series D and CEO Transition

Next
Next

Simcha Therapeutics announces first patient dosed in Ph1/2 study evaluating ST-067 in combination with KEYTRUDA® (Pembrolizumab)